FONT-SIZE Plus   Neg

Pernix Subsidiaries Receives Approval For VITUZ, Mefenamic Acid Capsules

Hawthorn Pharmaceuticals, Inc., a subsidiary of Pernix Therapeutics Holdings, Inc. (PTX) Thursday said it has received approval from the U.S. Food and Drug Administration, or FDA, for VITUZ Oral Solution.

VITUZ solution is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older.

The company also said that its subsidiary, Cypress Pharmaceuticals, Inc., has been granted final approval by the FDA for Mefenamic Acid Capsules USP, 250 mg, a generic version of Ponstel Capsules, 250 mg, indicated for relief of mild-to-moderate pain in patients treated of primary dysmenorrhea.

"VITUZ broadens our cough and cold product line and is our first NDA approved by the FDA, since the acquisition of Hawthorn and Cypress, " said Cooper Collins, President, CEO.

Launch of the new treatment option for cough and cold symptoms is expected prior to the fall of 2012. Mefenamic Acid Capsules are expected to launch in the second quarter.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Xbox Live users are aggravated about repeated outages that have prevented gamers from accessing online multiplayer features. Blaming higher egg prices and other rising costs, Dunkin's Donuts will close 100 stores, all of them Speedway gas station and convenience store locations. Micron Technology, Inc. said that its fourth quarter profit fell 59% from last year, as sales declined and gross margins deteriorated amid weak demand and pricing pressures due to continued softness in the personal computer market. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly sales.
comments powered by Disqus
Follow RTT